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Abstract  
Gastrointestinal follicular lymphoma (GI-FL) is a relatively rare disease, accounting for only 1% 
to 3.6% of gastrointestinal non-Hodgkin’s lymphoma. Although the duodenum and terminal 
ileum are considered to be the most common sites of origin, the development of wireless capsule 
endoscopy and double balloon enteroscopy has increased the detection of GI-FL in every part of 
the small intestine. Approximately 80% of patients with GI-FL are estimated to have multiple 
lesions throughout the entire gastrointestinal tract. 
FL is a low-grade lymphoma that usually develops very slowly. If the lymphoma causes no 
symptoms, immediate treatment may not be necessary. Standard therapy has not yet been 
established for GI-FL, but chemotherapy, radiotherapy, monoclonal antibody therapy, or a 
combination of these therapies is sometimes performed based on the therapeutic regimens for 
nodal FL. Regimens including conventional chemotherapy with rituximab, which achieve high 
response rates in nodal FL, are commonly used for GI-FL.  
The long-term clinical outcome of GI-FL is unclear. The results of a few series on the long-term 
outcomes of patients with GI-FL treated with conventional therapy indicate a median 
relapse-free time ranging from 31 to 45 months. On the other hand, in patients with GI-FL who 
were followed without treatment, the median-time to disease progression was 37.5 months. Thus, 
whether to initiate aggressive therapy or continue watchful-waiting in cases of GI-FL is a 
critically important decision. Ongoing research on biomarkers to guide individualized GI-FL 
therapy may provide invaluable information that will lead to the establishment of a standard 
therapeutic regimen. 
Key words: follicular lymphoma, gastrointestinal tract, multiple lymphomatous polyposis 
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INTRODUCTION 
Follicular lymphoma (FL) is one of the most common subtypes of non-Hodgkin’s lymphoma in 
the Western world, although its incidence may be lower in some parts of the world such as Asia 
[1]. Most cases of FL are initially detected in the lymph nodes and involvement of extranodal 
sites usually occurs only as a result of disseminated nodal disease [2]. The gastrointestinal (GI) 
tract is the most common site of extranodal non-Hodgkin’s lymphoma (NHL), accounting for 
30% to 40% of all primary extranodal NHL. [3, 4] The histologic subtypes in most primary 
GI-NHL are mucosal-associated lymphoid tissue (MALT) lymphoma or high-grade B cell 
lymphoma [5-8]. GI-FL is rare and the frequency of this entity accounts for 1% to 3.6% of 
GI-NHL [8-10]. The diagnosis, prognosis, and treatment of GI-FL remain largely unknown 
because of its rare frequency. In this article, the clinical, biologic, and endoscopic characteristics, 
as well as the outcome of these lymphomas are reviewed based on the literature and our 
experience.  
1. CLINICAL FEATURES 
To our knowledge, 244 cases with primary GI-FL have been reported with precise descriptions in 
the English literature [2, 8, 11-57]. The clinical features of 249 GI-FLs, including the 244 
reported cases and 5 unpublished cases that we experienced, are summarized in Table 1. 
1.1. Demographic features 
The median age of patients at diagnosis of GI-FL is 56 years (range 26-81), similar to that of 
nodal FL [58, 59]. In several case series of GI-FL, a female predominance was observed [8, 11, 
12], but other case series demonstrated an equal sex distribution in GI-FL [15-18]. Sato et al. 
[18], who reported the largest case series for GI-FL, described an equal sex distribution in GI-FL. 
Based on the available data of all reported cases, there is an equal sex distribution (122 females 
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and 124 males), which is similar to the sex distribution of nodal FL. 
In contrast to geographic distribution of nodal FL [1], of the 249 cases with GI-FL, almost 50% 
(120) are Japanese cases [8, 13, 14, 17, 19-39]. This geographic predominance may be due to 
higher frequency of endoscopic examination in Japan compared with the other countries, because 
50 (84.7%) of the 59 patients with GI-FL in Japan presented with no symptoms or only vague GI 
symptoms, while only 29 (32.2%) of 90 patients from other countries were asymptomatic.  
1.2. Clinical symptoms 
In most of the asymptomatic patients with GI-FL, the lesions were incidentally detected during 
routine esophagogastroduodenoscopy (EGD). Of 150 patients whose clinical symptoms at 
presentation are described in the literature, 65 (43.3%) were asymptomatic and 14 (9.3%) 
complained of vague GI symptoms such as abdominal discomfort or heartburn.  
Abdominal pain was present in 43 of 150 patients (28.7%). Symptoms of intestinal obstruction, 
such as nausea and vomiting, were present in 12 (8.0%) and symptoms of intestinal bleeding, 
such as tarry stool or hematochezia, were present in 9 (6.0%). Intestinal obstructions usually 
occurred in cases with small intestinal lesions, whereas bleeding was observed mostly in cases 
with colorectal lesions (Table 2). In some cases, patients with GI-FL have a protein losing 
enteropathy [16, 22, 40-43]. 
1.3. Clinical stage 
In GI-FL, most cases are classified using the Ann Arbor staging system [60] or the Lugano 
staging classification of GI tract lymphoma, which is a modified version of the Ann Arbor 
staging system for GI-NHL [61] (Table 3).  
Whereas most patients with nodal FL have systemic disease (i.e., stage III or IV) at the time of 
diagnosis [62], of 193 GI-FL patients with available clinical stage data, 128 (66.3%) were at 
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stage I and 52 (26.9%) were at stage II. Bende et al. [45] and Takata et al. [63] speculated that 
the low tendency of GI-FL to disseminate outside the GI tract is a distinct entity that originates 
from local antigen-responsive B cells in the intestinal mucosa. Bende et al. demonstrated that 
GI-FLs express alpha4beta7 integrin, a well-defined mucosal homing receptor not expressed in 
nodal FLs. In addition, GI-FL has a higher frequency of grade 1 lymphoma than nodal FL (see 
Histologic grading). The higher ratio of localized disease in GI-FL, however, may be due to the 
definition of GI-lymphoma rather than to a different tumor cell origins, because cases with both 
intestinal and massive extra-intestinal lesions are excluded from primary GI-FL (see Definition 
of primary GI lymphoma).  
On the other hand, GI-FL can involve regional lymph nodes even in cases in which the primary 
lesion involves only the mucosal or submucosal layer [8, 28, 33, 44, 46]. GI-FL tends to involve 
only regional lymph nodes, although it occasionally disseminates outside the GI tract and its 
regional lymph nodes. Yoshino et al. [8] suggested that this discrepancy is likely a result of the 
intricate muscle layer structures around the ampulla of Vater, because most intramural FL with 
regional lymph node dissemination involves this location [8, 28, 33]. 
1.4. Disease distribution in the GI tract 
GI-FL may infiltrate unifocally or multifocally, and disease distribution is very important for 
deciding therapy, i.e., radiation therapy may be effective for unifocal local diseases and 
rituximab therapy with or without chemotherapy may be required for multifocal diseases. A 
relatively large case series reported that GI-FL predominantly involved the duodenum, especially 
around the ampulla of Vater, or the terminal ileum unifocally. In the series reported by Sato et al. 
[18], 40 of 52 cases of extranodal FL (a number of cases with GI-FL were not described) arose in 
the duodenum, and in another series reported by Shia et al. [15], duodenal FL accounted for 10 
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of 26 cases of FL of the GI tract, while Le Brun et al. [11] reported that 55% of the lymphomas 
occurred in the small intestine, where they showed a predilection for the terminal ileum. Damaj 
et al. [12] reported that the most frequent site of involvement was the small intestine, with a 
predilection for the ileum and ileo-cecal region. Huang et al. [16] reported that the most frequent 
site was the ileum (7 of 13 cases, 54%) with 4 tumors in the terminal ileum.  
On the other hand, some cases of GI-FL have lesions resembling multiple lymphomatous 
polyposis (MLP). MLP is characterized by numerous polypoid lesions (Figure 1) involving long 
segments of GI tract and is a very rare entity, accounting for 2% of primary GI lymphomas [22]. 
Although first recognized in the 19th century by Briquet, [64] malignant lymphoma that 
presented as multiple small nodules affecting the long segment of the GI tract had been paid little 
attention until 1961 when Cornes referred to this disease entity as “multiple lymphomatous 
polyposis” [65]. MLP was initially considered to be a typical feature of mantle cell lymphoma 
(MCL) [66], but later studies indicated that MLP comprises a heterogeneous group of neoplasms, 
including MCL, FL, and MALT lymphomas [20, 67]. Since Le Brun et al. [11] reported that 5 of 
31 cases (16.1%) with GI-FL had a multiple polypoid appearance, several case series on GI-FL 
demonstrated that 15.0% to 46.2% of GI-FL has MLP aspects [12, 16, 18]. In these reports, 
however, the whole GI tract was not evaluated in all cases. Because MLP involves the long 
segment of the GI tract and is often discontinuous [23, 65], the frequency of GI-FL cases with 
MLP may actually be lower than in these reports. Two innovative methods to observe the entire 
small intestine were recently introduced: wireless capsule endoscopy (WCE) and double balloon 
enteroscopy (DBE). Both modalities allow high resolution visualization of the whole small 
intestine (see endoscopic examination). At present, there are 3 case series of GI-FL in which the 
whole GI tract was examined using EGD, colonoscopy, and DBE. In these reports, the proportion 
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of GI-FL with involvement at two or more sites of the GI tract was much higher than that in 
previous reports on GI-FL. Nakamura et al. [14] reported that 4 of 5 cases (80%) of GI-FL 
presented with multiple polypoid lesions resembling MLP in long segments of the jejunum or the 
ileum. In a case series by Kodama et al. [13], DBE showed new lesions in the jejunum or the 
ileum in 8 of 11 patients (73%) in whom GI-FL was detected in the duodenum with EGD. 
Higuchi et al. [32] reported that jejunoileal FL lesions were detected with DBE in 6 of 7 patients 
(85.7%) with FL in the duodenum. 
Data on the disease distribution of GI-FL based on the English literature and our unpublished 
cases, are summarized in Table 4. Before the introduction of WCE and DBE, it was reported that 
most GI-FLs were unifocal (176 of 216 cases, 81.5%) and the most frequent site was the 
duodenum (95 cases, 54.0%) followed by the ileum including the terminal ileum (28 cases, 
15.9%). On the other hand, in 33 cases with GI-FL where the entire intestine was examined with 
endoscopy including WCE or DBE, 24 patients (72.7%) suffered from GI-FL with multifocal 
involvement, and the proximal small intestine including the duodenum and the jejunum was the 
most frequent site of invasion. 
Although there is only a small number of cases of GI-FL in which WCE or DBE was performed, 
the frequency of GI-FL with long segmental GI tract involvement appears to be much higher 
than previously reported. Further investigation with WCE or DBE will be useful for accurately 
evaluating the disease distribution of GI-FL. 
2. DIAGNOSIS 
The diagnosis of primary GI-FL consists of two aspects. One is to diagnose FL as a 
clinicopathologic subset, and the other is to judge whether lymphoma arises from the GI tract or 
involves the GI tract as a result of dissemination from the primary site.  
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2.1. Definition of primary GI lymphoma 
It is not always possible to determine the primary site of origin of lymphoma involving the GI 
tract, especially in cases with both GI and extra-GI involvement. There are two possibilities of 
GI involvement of lymphoma cells. First, lymphoma arising from regions other than the GI tract 
presents in the GI tract with an advanced stage of generalized disease. Second, primary GI 
lymphomas can disseminate and involve lymph nodes or other extra-intestinal sites. At present, 
there is no way to distinguish whether the GI tract is the primary site or a secondary site 
representing an advanced stage of FL involving the GI tract.  
There are several definitions of primary GI lymphoma and at least two of them are widely used. 
One is the definition by Dawson et al. [68] put forth in 1966 that restricts GI lymphoma as a 
localized disease without involvement of peripheral or mediastinal lymph nodes, liver or spleen. 
The other is the definition by Lewin et al. [9], which extends to a wider range of presentations 
and requires that patients exhibit GI symptoms or a predominant lesion with or without 
extra-intestinal lesions. In most case series of GI-FL, the definition by Lewin et al. was applied 
and cases with massive extra-intestinal lesions were excluded from primary GI-FL [11, 12, 
15-17].  
2.2. Endoscopic examination 
2.2.1. Modality of endoscopic examination 
Endoscopic examinations allow for direct observation and biopsy of the GI tract, and biopsy 
specimens can be subjected to morphologic evaluation as well as immunohistochemical 
evaluation and molecular analysis. This modality is essential for diagnosing lymphoma, defining 
the extent of bowel involvement, and assessing the efficacy of treatment. However, it is very 
difficult to observe entire small intestine with conventional endoscopy, including EGD, 
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colonoscopy, and push enteroscopy. The recent development of WCE and DBE has enabled 
observation of the entire GI tract.  
WCE, first reported by Iddan et al. in 2000 [69], transmits images at a rate of two frames per 
second for over 8 hours, permitting acquisition of over 50 000 images [70]. The DBE system 
developed by Yamamoto et al. [71] in 2003 enables deep insertion of an endoscope to the small 
intestine by preventing over-stretching of the intestinal tract with an attachable balloon at its tip 
and a soft overtube with another balloon at the distal end [71]. These methods allow for detailed 
observation of the mucosa of the deep small intestine and have provided new data regarding the 
distribution of GI-FL (see Disease distribution in GI tract). 
WCE is a noninvasive outpatient procedure; sedation is unnecessary and there is no risk of 
exposure to x-rays. On the other hand, DBE can be used to obtain biopsy specimens of the small 
intestine far from the mouth or anus and to perform endoscopic therapeutic interventions, which 
cannot be done with WCE. Therefore, WCE appears to be suitable for screening examinations 
and for assessing treatment efficacy, but DBE is recommended for cases in which histologic 
evaluation is necessary or intestinal stenosis is suspected.     
2.2.2. Characteristic endoscopic findings 
For 183 of 249 cases with GI-FL, a precise description of the endoscopic findings is available 
and these are summarized in Table 5. In 95 of these cases, endoscopic findings represented 
whitish small polypoid, confluent or scattered lesions or nodules, with a 1 to 2-mm diameter 
(Figure1, 2a, b), described as “multiple polypoid lesions”, “multiple whitish small polyps”, 
“dense and numerous sessile polyps”, “yellow-whitish multiple granules”, or “multiple nodular 
lesions”. Magnifying endoscopic examination revealed that these whitish small nodules are 
enlarged and fused villi and that the mucosa of these lesions has a normal appearance, which is 
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suggestive of a subepithelial or submucosal lesion (Figure 3) [23, 25, 36, 38]. Endoscopic 
ultrasonography reveals thickening of the mucosal and submucosal layers of the intestinal wall 
with multiple hypoechoic granules corresponding to the lesions [19, 25, 26, 44]. These findings 
suggest that each granule is an enlarged neoplastic follicle that consists of lymphoma cells in the 
lamina propria, which has been confirmed with histologic examination (Figure 4a-d). 
Aggregation of such nodules can be unifocal or multifocal throughout the entire GI tract (see 
Disease distribution in the GI tract) and is characteristic of lymphoid hyperplasia and low 
grade B cell lymphoma, including MALT lymphoma with follicular colonization, FL, and MCL. 
In some cases, macroscopic findings alone are not sufficient to distinguish between these disease 
subsets [20] (Figure 5), and pathologic examinations, immunohistochemical staining, and 
molecular analysis are necessary in such cases. Because the prognosis for MALT lymphoma, FL, 
and MCL is quite different [20], it is very important to establish a differential diagnosis of these 
diseases. Therefore, obtaining biopsy specimens for histopathologic evaluation, including 
immunohistochemical staining and molecular analysis, is strongly recommended when this 
characteristic finding is observed. 
The second most common finding is a mass lesion with or without ulceration (38 cases). Mass 
lesions sometimes present with a submucosal tumor-like appearance (Figure 6a, b, Figure 7 a). In 
approximately 50% of cases of GI-FL with a mass lesion, however, multiple nodular lesions are 
observed at other sites in the GI tract (Figure 7 b). Therefore, in most cases with GI-FL, multiple 
nodular lesions might be observed in the early stage.  
Endoscopy usually reveals multiple polypoid lesions in the duodenum, jejunum, ileum, and 
colon. Detailed macroscopic findings are available for only 2 of 13 cases reported as primary 
gastric FL [21, 37]. In both cases, the macroscopic appearance of FL was submucosal tumor-like 
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(Figure 6 a, b) and could not be distinguished from the other subtypes of GI lymphoma, 
especially diffuse large B cell lymphoma, which is one of the most common types of high-grade 
gastric lymphoma. Rectal lesions of GI-FL sometimes present as a single elevated mass like a 
polyp [36]. GI-FL rarely involves the esophagus and there are only 3 cases in which an 
esophageal lesion was observed [20, 22] and in all cases the esophageal lesion presented as a part 
of MLP. 
2.3. PATHOLOGY AND BIOLOGY  
GI tract and skin are reported to be the most common sites for primary extranodal FL [2]. 
Primary cutaneous FL is considered to be a distinct entity from nodal FL because of the lack of 
t(14;18)(q32;q21) and the relatively favorable response to treatment [72-75], although FL in this 
site shares some features with nodal FL, such as cell morphology and growth pattern. These 
findings raise the possibility that FL arising in the GI tract can be distinguished from FL 
normally found in lymph nodes as considered in cutaneous FL. In conclusion, morphologic 
futures, immunophenotype, and presence of t(14;18)(q32;q21) suggest that primary GI-FL may 
be more closely related to nodal FL than cutaneous FL or other primary GI-lymphoma, although 
some reports on GI-FL have emphasized the differences between GI-FL and nodal FL [18, 45, 
63]. 
2.3.1. Morphology 
2.3.1.1 Microscopic findings 
The morphologic features of GI-FL cannot be distinguished from those of nodal FL [45]. In the 
typical GI-FL case, the follicles are approximately the same size as a mature germinal center, 
uniform in size, closely packed, and lacking a mantle zone, presenting in the lamina propria of 
the intestinal mucosa at the early stage (Figure 4 a) and transmural at an advanced stage. The 
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centrocytes, which are usually less than twice the size of small lymphocytes and whose nuclei 
are irregular [76], and centroblasts, which are usually three to four times the size of small 
lymphocytes and whose nuclei are round but may be irregular [76], of GI-FL are identical to 
those of normal germinal centers. A starry-sky pattern with phagocytic histiocytes is usually 
absent in GI-FL [45], as well as nodal FL [76]. 
In most cases with GI-FL, the tumor cells do not infiltrate and destroy the gland epithelium, i.e., 
there is no lymphoepithelial lesion, which is one of the characteristic findings of MALT 
lymphoma. Tzankov et al. [48], however, reported a case with gastric FL in which a 
lymphoepithelial lesion was observed and Takeshita et al. [77] reported that lymphoepithelial 
lesions occurred in 2 of 12 CD10-positive diffuse large cell lymphomas of the stomach that had a 
germinal center B-cell phenotype. Thus, the presence of a lymphoepithelial lesion may not 
exclude the possibility of FL, especially in gastric lymphoma. 
2.3.1.2. Histologic grading 
In most cases with GI-FL as well as nodal FL, FL is categorized into three grades based on the 
Berard criteria [78], according to the number of centroblasts (large nucleolated cells) per 
high-power field. In nodal FL, several studies suggest that this grading is a good predictor of 
prognosis, [79, 80] and grade 3b FL tends to behave similarly to de novo diffuse large B cell 
lymphoma with earlier relapses and a shorter survival [81]. Frequencies of grade 1, grade 2, and 
grade 3 in GI-FL are 84.4%, 11.3% and 4.3%, respectively (Table 6), while those of grade 1, 
grade 2, and grade 3 in nodal FL are 40% to 60%, 25% to 35%, and approximately 20%, 
respectively [76]. This may be one of the reasons why GI-FL tends to be detected at an earlier 
stage and have a better overall survival rate than nodal FL (see Clinical stage and Prognosis of 
GI-FL).  
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2.3.2. Immunophenotype 
In GI-FL, as well as nodal FL, tumor cells are positive for pan-B-cell antigens, including CD19, 
CD20, and CD22, and negative for CD5 and cyclin D1 [45], which are characteristically 
expressed in MCL and small lymphocytic lymphoma/chronic lymphocytic leukemia [82]. 
Immunohistochemical staining for CD10 and bcl-2 is useful for distinguishing FL from 
lymphoid hyperplasia, MALT lymphoma, or MCL [76]. Both CD10 and bcl-2 are expressed in 
approximately 90% of cases with GI-FL (Table 7, Figure 4c, d), while normal germinal center 
cells express CD10 but not bcl-2 (Figure 5d, e). MCL expresses neither CD10 nor bcl-2, and 
MALT lymphoma is negative for CD10 and occasionally positive for bcl-2 [76]. 
Bende et al. [45] demonstrated that GI-FL expressed alpha4beta7 integrin, a well-defined 
mucosal homing receptor and surface IgA, in contrast to nodal FLs, and speculated that GI-FL is 
a distinct entity that originates from local antigen-responsive B cells in the intestinal mucosa. No 
other reports, however, have confirmed that GI-FL expresses alpha4beta7 integrin. In addition, 
only 1 of 23 other cases in which the surface immunoglobulin of tumor cells was examined 
expressed IgA, and GI-FL most often expressed surface IgM, followed by IgD (Table 7) [16, 19, 
22, 34, 46, 47], similar to nodal FL. Therefore, further evaluation is necessary to elucidate 
whether or not GI-FL has a different immunophenotype, including alpha4beta7 integrin and 
surface immunoglobulin, compared to nodal FL. 
2.3.3. Genetic features 
In 70% to 95% of nodal FL, t(14;18)(q32;q21), which causes a fusion of BCL2 with the 
immunoglobulin heavy chain joining region and prevents the normal switching off of BCL2, is 
present [83-85]. On the other hand, most primary cutaneous FL lacks t(14;18)(q32;q21) [72-75]. 
Thus, in cases with GI-FL, the presence of this chromosomal rearrangement is examined with 
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Southern blotting, polymerase chain reaction (PCR) (Figure 7 c, Figure 8), or fluorescence in situ 
hybridization (FISH) (Figure 7 d). 
Southern blotting, PCR, and FISH demonstrated the presence of an IgH/BCL2 rearrangement in 
60%, 57.1%, and 70% of GI-FLs, respectively (Table.8), the same frequency as in nodal FL. 
PCR analysis for GI-FL seems to be less sensitive than FISH analysis, as described for nodal FL 
[86-89]. In all cases in which t(14;18)(q32;q21) was not detected by PCR analysis, the 
breakpoint used for diagnosis was a major break region (MBR) [90], at which the breakpoint is 
located in only 50% to 60% of nodal FL [86, 91], and other breakpoints including the minor 
cluster region (mcr), 3’ BCL2, 5’mcr, and intermediate cluster region (icr) [92-95] were not 
evaluated. Therefore, in such cases additional PCR analysis using primers for other BCL2 
breakpoints or FISH analysis may be more sensitive. 
FISH and PCR analysis can be performed on fresh, frozen, or fixed paraffin-embedded material 
[96]. In addition, FISH analysis can demonstrate IgH/BCL2 rearrangement regardless of the 
location of BCL2 breakpoint and its probes do not require absolute sequence complementarity 
for detecting the rearrangement [96]. In both nodal FL [86] and GI-FL, FISH analysis seems to 
be superior to PCR analysis in detecting t(14;18)(q32;q21) (Table 8).  
Taken together, the presence of t(14;18)(q32;q21) suggests that primary GI-FL is more closely 
related to nodal FL than cutaneous FL and demonstrates that the IgH/BCL2 rearrangement is 
useful for diagnosing GI-FL and nodal FL, with equivocal morphologic and immunophenotypic 
findings. Given its superior diagnostic sensitivity, FISH should be considered as an initial 
diagnostic method to detect t(14;18)(q32;q21) or an alternative method for negative cases with 
PCR, which is a less expensive and faster technique to perform than FISH. Therefore, for 
diagnosis of GI-FL, biopsy specimens for fixation with formalin and for FISH or PCR analysis 
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should be obtained for higher diagnostic sensitivity. 
Takata et al. [63] reported that duodenal FL cells showed accumulation of somatic 
hypermutation and ongoing mutations in spite of the lack of activation induced cytidine 
deaminase expression and their follicular dendritic cell network formation, which is similar to 
neoplasic marginal zone-like B cells. In addition, they demonstrated that duodenal FL had a 
restricted usage of variable region of immunoglobulin heavy chain gene (VH). Duodenal FL of 
their series had a higher usage of VH4 and VH5 than nodal FL and VH4-34 and VH5-51were 
detected in many of these cases. They speculated that these findings should indicate that the 
lymphoma cells are derived from B cells reacting with specific antigens, as in the case of MALT 
lymphoma, which develops from chronic inflammation such as Helicobacter pylori (HP)-related 
gastritis. 
3. STAGING  
Accurate staging of GI-FL is important because durable remissions, and in some cases cures, can 
be achieved with surgical resection or external-beam radiotherapy of the affected area in patients 
with localized disease. (see GASTROINTESTINAL FOLLICULAR LYMPHOMA 
TREATMENT) 
3.1. Staging procedures 
Staging procedures for GI-FL are almost the same as those routinely used for nodal FL. In 
addition to a staging work-up, however, including an accurate physical examination, complete 
hematologic and biochemical examinations, total-body computerized tomography (CT), and 
bone marrow aspirate and biopsy, evaluation of the whole GI tract using EGD, colonoscopy, and 
total enteroscopy (i.e., WCE or DBE) are necessary to determine GI-FL staging because GI-FL 
often involves long segments of the GI tract (see Disease distribution in the GI tract).  
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3.2. Recent advances in gastrointestinal follicular lymphoma staging 
Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) scanning has 
recently emerged as a major imaging modality for the staging and follow-up of patients with 
lymphoma, especially aggressive lymphomas [98, 99]. FDG-PET scanning has excellent 
sensitivity and specificity for staging in nodal FL as well, in contrast to other indolent 
lymphomas, including B-cell small-cell lymphocytic lymphoma, marginal zone lymphoma, and 
MCL [100-102]. 
There are few reports in which FDG-PET was performed for staging in GI-FL [24, 32, 37, 41, 
44]. In 14 of 16 cases with FL of the small intestine, there were no obvious accumulations of 
18F-FDG in the primary lesions. Focal 18F-FDG uptake in the primary site was observed in 1 
case with gastric FL [37] and 2 cases with FL of the small intestine [32]. In all of these cases, the 
primary lesion formed a mass lesion. It is noteworthy that small mediastinal lymph node 
dissemination was detected with FDG-PET in one gastric FL case (Figure 6 c, arrowhead) [37]. 
In this case, the disseminated lesion above the diaphragm could not be detected with CT, which 
was performed before FDG-PET examination. In another case with duodenal FL [24], 18F-FDG 
accumulated in the mesenteric lymph nodes, whereas there was no obvious uptake in the primary 
site. Therefore, this modality may not be useful for evaluating the spread of the primary lesion, 
as Hoffman et al. [44] and Higuchi et al. [32] demonstrated, but is useful for evaluating lymph 
node dissemination. 
4. PROGNOSIS IN PATIENTS WITH GASTROINTESTINAL FOLLICULAR 
LYMPHOMA 
4.1. Prognosis of GI-FL 
The long-term clinical outcome of GI-FL remains unclear because there has been no analysis of a 
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large population-based registry of survival for patients with GI-FL. In a case series on long-term 
outcomes of patients with GI-FL, relapse-free median time or median relapse-free survival was 
similar to that for nodal FL [12, 15]. Shia et al. [15] reported a median relapse-free survival of 63 
months in 25 GI-FL patients. Damaj et al. [12] reported a median time to progression of 37.5 
months in 7 patients without any treatment and a median time to recurrence of the disease of 31 
months in 18 patients with treatment.  
On the other hand, based on all available data reported previously, GI-FL seems to have a better 
prognosis than nodal FL. There are only five reported cases in which the patients died of GI-FL 
and 3 patients died of another disease among 249 GI-FL patients [12, 20, 22, 54]. In addition, the 
median relapse-free survival was 98 months in 96 patients with GI-FL (Figure 9 a), which 
appears to be a more favorable outcome compared with nodal FL. 
In GI-FL, the frequency of grade 1 lymphoma is much higher compared with nodal FL (see 
Histologic grading), and most GI-FL presents as a localized disease at the time of diagnosis, 
while most nodal FL involves multiple sites when staging procedures are performed (see 
Clinical stage). These features may indicate that GI-FL is a distinct entity from nodal FL, and is 
slower to progress. 
There may be other reasons for the better prognosis of GI-FL than nodal FL. When lymphoma 
cells infiltrate not only the GI tract but also extra-intestinal sites, e.g., peripheral or mediastinal 
lymph nodes, liver or spleen, most such cases, especially those with massive extra-intestinal 
lesions, are excluded from primary GI-FL [11, 12, 15-17] because of the inability to distinguish 
between primary GI-FL with extra-intestinal invasion and secondary GI-FL as a result of 
dissemination from another site (see Definition of primary GI lymphoma). Second, there are 
only a few GI-FL patients with a long-term follow-up because of its rarity. The median-follow up 
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duration of the reported cases with GI-FL is only 24.5 months, while the median follow-up was 
more than 50 months in most studies on long-term clinical outcome of nodal FL [103-105]. 
Grade 1 GI-FL tends to have a better relapse-free survival than grade 2 GI-FL, but the prognosis 
for grade 3 lymphoma is unclear because of its rarity. Relapse-free survival of grade 1, grade 2, 
and grade 3 is 61.6% at 180 months (n=48), 41.7% at 112 months (n=13), and 100% at 108 
months (n=3), respectively (Figure 9 b). The difference in overall survival between each grade is 
also unknown, as only 5 patients died of GI-FL and 3 died of other diseases based on the 
available literature [12, 20, 22, 54]. 
To compare the prognosis between localized GI-FLs ( i.e., stage I or II) and systemic ones (i.e., 
stage III or IV) is difficult, because only 13 of 193 GI-FL patients (6.7%) with available clinical 
stage data had a systemic disease. 
4.2. Recurrence after achieving complete remission in GI-FL 
Of 249 patients with GI-FL, 85 achieved complete remission with various therapies (see 
GASTROINTESTINAL FOLLICULAR LYMPHOMA TREATMENT). Of those, FL 
relapsed in 16 cases from 1 to 98 months after achieving complete remission [12, 15-17, 47]. 
Details about relapsed cases are summarized in Table 9. Median time to recurrence was 44.5 
months. Initial treatments to induce remission were surgery (4 cases), radiation (1 case), 
chemotherapy (4 cases), radiation plus chemotherapy (2 cases), surgery plus chemotherapy (4 
cases), and radiation plus surgery following chemotherapy (1 case). It is noteworthy that FL 
relapsed outside the GI tract, including in extra-abdominal lymph nodes, the spleen, and tonsils 
in about 50% of recurrent cases [15-17]. Therefore, not only evaluation of GI-tract using 
endoscopy and abdominal CT scan, but also whole body evaluation, including gallium 
scintigram or FDG-PET, should be performed for follow-up studies after achieving complete 
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remission. To screen for extra-abdominal relapse, FDG-PET rather than gallium scintigraphy is 
recommended because of its sensitivity [100] (see Recent advances in gastrointestinal 
follicular lymphoma staging).  
5. GASTROINTESTINAL FOLLICULAR LYMPHOMA TREATMENT 
Management of GI-FL is controversial, mainly because of its rarity. Damaj et al. [12] reported 
that there was no significant difference in the prognosis between patients without treatment and 
those with treatment, as in nodal FL [106-108]. Therefore, a “watch and wait policy” has been 
adopted in some asymptomatic cases with GI-FL [13, 15, 17, 18, 20, 23, 54, 55]. In other cases, 
surgery, radiotherapy, chemotherapy, monoclonal antibody therapy, or the combination of these 
therapies is performed. In addition, antibiotic therapy has been tried in several cases of GI-FL [7, 
17-19, 24, 25, 34, 50], based on the established efficacy of antibiotics in cases with other 
indolent GI lymphomas, such as gastric MALT lymphoma or immunoproliferative small 
intestinal disease (IPSID).  
GI-FL treatments and responses are summarized in Table 10. 
5.1. Conventional therapies 
Patients with GI-FL have been treated with surgery, radiotherapy, chemotherapy, or the 
combination of these therapies. To compare the effect of each therapy with another is difficult, 
however, because the number of patients receiving each type of treatment is very small and the 
background of the cases, including clinical stage and duration of follow-up, varies. In general, a 
complete response was achieved in most patients regardless of treatment modality, reflecting the 
indolent nature of GI-FL (Table 9) (see Prognosis in patients with gastrointestinal follicular 
lymphoma). 
Chemotherapy for GI-FL is performed based on the therapeutic regimens of nodal FL, especially 
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in cases with systemic disease or widespread GI tract involvement. 
5.2. Rituximab-containing regimen 
After the introduction of therapies using the monoclonal antibody against CD20, rituximab, 
several randomized studies demonstrated that this therapeutic modality with conventional 
therapies improved not only the complete response rate and the duration of the response, but also 
the overall survival rate of nodal FL [109-111]. In addition, in GI-FL, immunotherapy using 
rituximab with or without chemotherapy has been performed [7, 13, 16-18, 20, 24, 28, 41, 42, 
56], although the efficacy of therapy including rituximab has not been compared with that of 
conventional therapy alone. There seems to be no difference in the response of GI-FL between 
therapeutic regimens containing rituximab and conventional therapy at present, which may be 
due to the disease rarity and the favorable nature of the disease (Table 9). 
5.3. Antibiotic therapy 
Growing evidence indicates that some subtypes of marginal zone lymphomas are associated with 
chronic antigen stimulation by microbial pathogens and that therapy with antibiotics is effective 
in marginal zone lymphoma of MALT type, including gastric MALT lymphoma and IPSID. 
Several studies revealed a close association of infection with HP and gastric MALT lymphoma 
[112-115] and the eradication of HP infection results in lymphoma remission in cases with 
low-grade MALT lymphoma localized in the stomach [116-122].  
IPSID, which is also called “Mediterranean lymphoma” or “alpha heavy chain disease” [123], is 
a variant of MALT lymphoma in the small intestine. Early-stage IPSID responds to antibiotics 
such as tetracycline, ampicillin, or metronidazole [124]. Recently Lecuit et al. reported that 
IPSID is associated with Campylobacter jejuni [125]. 
Also in GI-FL, some patients were treated with antibiotics using an HP eradication regimen, 
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because HP was detected in the stomach or a diagnosis of MALT lymphoma was made at first. 
Most GI-FL lesions, however, were unchanged or progressed despite the administration of 
antibiotic agents [17, 18, 24, 25, 50]. The fact that antibiotic therapy is ineffective for most cases 
with GI-FL may indicate that neoplastic follicles of GI-FL are not composed of antigen-driven 
cells, different from MALT lymphoma [126]. 
In several cases with GI-FL, however, regression of GI-FL was noted after antibiotic treatment 
[14, 19, 34]. Toyoda et al. reported a case with duodenal FL that regressed 12 months after 
eradication of HP, although the immunophenotype of the tumor cells was CD10- and bcl-2+, 
which is characteristic of MALT lymphoma rather than FL [19]. Nakamura et al. [14] described a 
patient who showed regression of GI-FL at 15 months after antibiotic treatment and Nomura et al. 
[34] reported that duodenal FL regressed at 12 months after antibiotic therapy. These cases may 
suggest that tumor cell growth depends on stimulation with antigens originating from the gut 
lumen via B cell receptors on the tumor cells in some cases with GI-FL, as Bende et al. [45] and 
Takata et al. [63] speculated. 
6. CONCLUSION  
Although GI-FL is generally considered to be a rare entity, the number of reported cases with 
GI-FL is increasing. A consensus regarding the management of this disorder, however, has not 
yet been established. Irrespective of the specific therapy, overall survival of GI-FL appears to be 
good. Little is known about long-term clinical outcome of GI-FL, especially since treatment with 
rituximab was introduced. Therefore, further studies are necessary to evaluate how rituximab 
changes the clinical outcome of GI-FL. 
Accurate evaluation of the distribution of the disease, however, is necessary for deciding the 
treatment modality. WCE and DBE, which provide detailed information about the mucosa of 
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whole small intestine, are useful for localizing GI-FL because of the potential multifocal 
involvement of the GI tract in many cases. GI-FL tends to be localized in the GI tract and 
regional lymph nodes at diagnosis, whereas extra-abdominal relapse is observed in about 50% of 
recurrent cases. Accordingly, endoscopic examination throughout the entire GI tract and whole 
body evaluation with FDG-PET is necessary for staging and follow-up studies. 
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Endoscopic findings of GI-FL in a 52-year-old man. DBE revealed multiple confluent polypoid 
lesions over approximately 50 cm of ileum proximal to the ileocecal valve. [29] 
Figure 2. 
Endoscopic findings of GI-FL in a 57-year-old woman. DBE demonstrated multiple 
yellow-whitish nodules of various densities in the duodenum and jejunum. [27]  
Figure 3.  
Endoscopic findings of GI-FL in a 57-year-old woman. EGD showed multiple whitish granules 
around the major duodenal papilla. Magnified endoscopic view revealed that the white granules 
comprised enlarged and fused villi. [23] 
Figure 4. 
Histologic findings of a granular GI-FL lesion in a 75-year-old woman with duodenal FL. 
Histologic evaluation of these granules revealed enlarged neoplastic follicles in the lamina 
propria of the duodenum. Lymphoepithelial lesions were absent (a). The lymphoid follicles 
comprised predominantly unvarying small-cleaved cells (b). Immunohistochemical staining for 
both CD10 (c) and bcl-2 (d) was positive. The diagnosis was FL, grade1 according to the WHO 
classification. 
Figure 5. 
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Endoscopic and histologic findings of lymphoid hyperplasia in a 61-year-old woman. EGD 
showed multiple polypoid lesions in the duodenal bulb that resembled GI-FL lesions (a, b). 
Biopsy revealed lymphoid follicles with normal architecture in the lamina propria of the 
duodenum (c). Immunochemical staining of germinal center cells was weakly positive for CD10 
(d), but negative for bcl-2 (e). The diagnosis was lymphoid hyperplasia. 
Figure 6. 
(a, b) Endoscopic findings of gastric FL and (c) FDG-PET findings of gastric FL in a 63-year-old 
man. EGD revealed a submucosal tumor-like lesion in the cardia of the stomach 3 years 
previously (a). This lesion progressed slowly and ulceration of the lesion was observed at the 
time of presentation (b). FDG PET revealed an accumulation of 18F-FDG in this lesion in the 
stomach (c, arrow). It is noteworthy that small mediastinal lymph node dissemination was 
detected with FDG-PET in this case (c, arrowhead). [37] 
Figure 7. 
(a, b) Endoscopic findings of GI-FL, (c) PCR analysis of GI-FL, (d) and FISH analysis of GI-FL 
in a 47-year-old man. DBE revealed an submucosal tumor-like lesion with ulceration in the 
middle portion of the small intestine (a). There were small whitish granular lesions on the oral 
side of the ulcer (b). PCR analysis. IgH/BCL2 rearrangement was detected with probes for MBR 
(c). FISH analysis. t(11;14)(q13;q32) was demonstrated by the yellow fusion signals in an 
abnormal nucleus (d). 
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Figure 8. 
PCR analysis in an 81-year-old woman with GI-FL. Primers for MBR failed to detect 
t(14;18)(q32;q21) (lane 2) and PCR products using primers for mcr were observed in lane 3. 
Figure 9. 
(a) Kaplan–Meier plots of relapse-free survival after achieving complete remission in cases with 
GI-FL. (b) Relapse-free survival according to histologic grade. Relapse-free survival of grade 1, 
grade 2, and grade 3 was 61.6% at 180 months (n=48), 41.7% at 112 months (n=13), 100% at 
108 months (n=3), respectively 
 
 
